4908

Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation agreed to pay 72.5 million to resolve civil False Claims Act allegations arising from the marketing of the cystic fibrosis drug TOBI. The settlement resolved allegations that, between Jan. 1, 2001 and July 31, 2006, Novartis and its predecessor, Chiron Corporation, caused false claims to be submitted to federal health care programs for certain off-label uses of the drug.